BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. develops therapeutic products primarily using adult stem cells and tissue protocols. The company was incorporated in Nevada on June 13, 1997, changed its name from "Stem Cell Assurance, Inc." to "BioRestorative Therapies, Inc." on August 15, 2011, reincorporated in Delaware effective January 1, 2015, and reincorporated in Nevada effective December 31, 2022. The company's Disc/Spine Program focuses on BRTX-100, an investigational therapeutic product for chronic lower back pain from degenerative disc disease. A U.S. patent for this program was issued in March 2022. BioRestorative Therapies is conducting a Phase 2 clinical trial for BRTX-100 and has obtained U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance to evaluate BRTX-100 for chronic cervical discogenic pain. The company holds an exclusive license for technology involving adult stem cell treatment for disc and spine conditions, including protruding and bulging lumbar discs. Additionally, the company is developing its pre-clinical ThermoStem Program, which uses brown adipose (fat) for cell-based treatment of type 2 diabetes, obesity, hypertension, other metabolic disorders, and cardiac deficiencies. Patents for the ThermoStem Program have been issued in the United States and other jurisdictions. BioRestorative Therapies also operates a commercial biocosmeceuticals business, offering a cell-based secretome containing exosomes, proteins, and growth factors, formulated and manufactured in its cGMP ISO-7 certified clean room, designed to reduce the appearance of fine lines and wrinkles and provide other cosmetic benefits.